Email updates

Keep up to date with the latest news and content from BMC Pulmonary Medicine and BioMed Central.

Open Access Highly Accessed Study protocol

Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial [NCT00120978]

Don D Sin1*, SF Paul Man1, Darcy D Marciniuk2, Gordon Ford5, Mark FitzGerald1, Eric Wong3, Ernest York4, Rajesh R Mainra6, Warren Ramesh7, Lyle S Melenka8, Eric Wilde9, Robert L Cowie5, Dave Williams10, Roxanne Rousseau1 and the ABC (Advair, Biomarkers in COPD) Investigators

Author Affiliations

1 Department of Medicine (Respiratory Division), University of British Columbia, Vancouver, Canada

2 Department of Medicine, University of Saskatchewan, Saskatoon, Canada

3 Department of Medicine, University of Alberta, Edmonton, Canada

4 Wetaskiwin General Hospital, Wetaskiwin, Canada

5 Department of Medicine, University of Calgary, Calgary, Canada

6 Lions Gate Hospital, North Vancouver, Canada

7 Royal Alexandra Hospital, Edmonton, Canada

8 Grey Nuns Hospital, Edmonton, Canada

9 Lethbridge General Hospital, Lethbridge, Canada

10 Matsqui-Sumas-Abbotsford General Hospital, Abbotsford, Canada

For all author emails, please log on.

BMC Pulmonary Medicine 2006, 6:3  doi:10.1186/1471-2466-6-3

Published: 6 February 2006

Abstract

Background

Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown. The Advair Biomarkers in COPD (ABC) study will determine whether the effects of inhaled corticosteroids alone or in combination with a long-acting β2-adrenoceptor agonist reduce systemic inflammation and improve health status in patients with chronic obstructive pulmonary disease.

Methods/Design

After a 4-week run-in phase during which patients with stable chronic obstructive pulmonary disease will receive inhaled fluticasone (500 micrograms twice daily), followed by a 4-week withdrawal phase during which all inhaled corticosteroids and long acting β2-adrenoceptor agonists will be discontinued, patients will be randomized to receive fluticasone (500 micrograms twice daily), fluticasone/salmeterol combination (500/50 micrograms twice daily), or placebo for four weeks. The study will recruit 250 patients across 11 centers in western Canada. Patients must be 40 years of age or older with at least 10 pack-year smoking history and have chronic obstructive pulmonary disease defined as forced expiratory volume in one second to vital capacity ratio of 0.70 or less and forced expiratory volume in one second that is 80% of predicted or less. Patients will be excluded if they have any known chronic systemic infections, inflammatory conditions, history of previous solid organ transplantation, myocardial infarction, or cerebrovascular accident within the past 3 months prior to study enrolment. The primary end-point is serum C-reactive protein level. Secondary end-points include circulating inflammatory cytokines such as interleukin-6 and interleukin-8 as well as health-related quality of life and lung function.

Discussion

If inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease.